Travere Therapeutics (TVTX) Share-based Compensation (2013 - 2026)
Travere Therapeutics' (TVTX) quarterly Share-based Compensation came in at $16.1 million in Q1 2026, up 40.5% YoY from $11.5 million in Q1 2025, and up 40.84% on a QoQ basis from $11.5 million in Q4 2025.
Travere Therapeutics (TVTX) Share-based Compensation (2013 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 14 years of Share-based Compensation data on file, last reported at $16.1 million in Q1 2026.
- Quarterly Share-based Compensation rose 40.5% year-over-year to $16.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.5 million (up 28.14% YoY) and the FY2025 annual result came in at $44.9 million, up 21.55% from the prior year.
- Share-based Compensation rose to $16.1 million in Q1 2026, from $11.5 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $16.1 million in Q1 2026 to a low of $8.0 million in Q3 2024.
- A 5-year average of $10.6 million and a median of $10.6 million in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 73.2% — and 2024, when it decreased 29.14%.
- Tracing TVTX's Share-based Compensation over 5 years: stood at $9.3 million in 2022, then declined by 12.4% to $8.1 million in 2023, then gained by 13.14% to $9.2 million in 2024, then increased by 24.42% to $11.5 million in 2025, then soared by 40.84% to $16.1 million in 2026.
- The last three Share-based Compensation figures came in at $16.1 million (Q1 2026), $11.5 million (Q4 2025), and $11.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 21.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.79 Mn |
| Jun 30, 2026 | 21.79 Mn |
| Mar 31, 2026 | 16.15 Mn |
| Mar 31, 2026 | 16.15 Mn |
| Dec 31, 2025 | 11.46 Mn |
| Dec 31, 2025 | 11.46 Mn |
| Sep 30, 2025 | 11.26 Mn |
| Sep 30, 2025 | 11.26 Mn |
| Jun 30, 2025 | 10.65 Mn |
| Jun 30, 2025 | 10.65 Mn |
| Mar 31, 2025 | 11.49 Mn |
| Mar 31, 2025 | 11.49 Mn |
| Dec 31, 2024 | 9.21 Mn |
| Dec 31, 2024 | 9.21 Mn |
| Sep 30, 2024 | 8.02 Mn |
| Sep 30, 2024 | 8.02 Mn |
| Jun 30, 2024 | 9.92 Mn |
| Jun 30, 2024 | 9.92 Mn |
| Mar 31, 2024 | 9.76 Mn |
| Mar 31, 2024 | 9.76 Mn |